Cargando…

Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines

 : DaxibotulinumtoxinA-lanm for injection (DAXI), a novel botulinum toxin type A formulation, contains a purified 150-kD core neurotoxin (daxibotulinumtoxinA) and proprietary stabilizing peptide (RTP004), and is approved for glabellar line treatment. As with any biologic product, DAXI may potentiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Humphrey, Shannon, Dover, Jeffrey S, Bowsher, Ronald R, Clancy, Amanda, Liu, Yan, Prawdzik, Gregg, Gallagher, Conor J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501746/
https://www.ncbi.nlm.nih.gov/pubmed/37051886
http://dx.doi.org/10.1093/asj/sjad101
_version_ 1785106177439301632
author Humphrey, Shannon
Dover, Jeffrey S
Bowsher, Ronald R
Clancy, Amanda
Liu, Yan
Prawdzik, Gregg
Gallagher, Conor J
author_facet Humphrey, Shannon
Dover, Jeffrey S
Bowsher, Ronald R
Clancy, Amanda
Liu, Yan
Prawdzik, Gregg
Gallagher, Conor J
author_sort Humphrey, Shannon
collection PubMed
description  : DaxibotulinumtoxinA-lanm for injection (DAXI), a novel botulinum toxin type A formulation, contains a purified 150-kD core neurotoxin (daxibotulinumtoxinA) and proprietary stabilizing peptide (RTP004), and is approved for glabellar line treatment. As with any biologic product, DAXI may potentially be immunogenic and elicit unwanted antibody formation, possibly resulting in partial or complete treatment failure. The immunogenicity of DAXI was assessed in 2 double-blind, placebo-controlled, single-dose studies and an open-label safety study of up to 3 repeat treatments. Of the 2737 evaluable patients, none developed neutralizing antibodies to daxibotulinumtoxinA and 0.8% developed treatment-related nonneutralizing anti–daxibotulinumtoxinA-binding antibodies. Of evaluable patients exposed to RTP004 with either DAXI or placebo, 1.3% developed treatment-related anti–RTP004-binding antibodies, which were mostly transient. No patient developed binding antibodies to both daxibotulinumtoxinA and RTP004. All patients with treatment-related binding antibodies to daxibotulinumtoxinA or RTP004 achieved a clinical response (none or mild glabellar line severity) at Week 4 following each DAXI treatment cycle. The duration of clinical response was not different between treatment cycles when antibodies were detected vs when they were absent. Although the analysis population was small compared to the number of patients likely to receive repeated treatment in clinical practice, these results suggest that DAXI administration at the approved glabellar lines dose has low immunogenic potential and that nonneutralizing antibodies to daxibotulinumtoxinA or RTP004 occur infrequently and often transiently, and have no impact on clinical efficacy, safety, or duration of action. Real-world data encompassing larger numbers of patients is needed to substantiate these results. LEVEL OF EVIDENCE: 3: [Image: see text]
format Online
Article
Text
id pubmed-10501746
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105017462023-09-15 Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines Humphrey, Shannon Dover, Jeffrey S Bowsher, Ronald R Clancy, Amanda Liu, Yan Prawdzik, Gregg Gallagher, Conor J Aesthet Surg J Special Topic  : DaxibotulinumtoxinA-lanm for injection (DAXI), a novel botulinum toxin type A formulation, contains a purified 150-kD core neurotoxin (daxibotulinumtoxinA) and proprietary stabilizing peptide (RTP004), and is approved for glabellar line treatment. As with any biologic product, DAXI may potentially be immunogenic and elicit unwanted antibody formation, possibly resulting in partial or complete treatment failure. The immunogenicity of DAXI was assessed in 2 double-blind, placebo-controlled, single-dose studies and an open-label safety study of up to 3 repeat treatments. Of the 2737 evaluable patients, none developed neutralizing antibodies to daxibotulinumtoxinA and 0.8% developed treatment-related nonneutralizing anti–daxibotulinumtoxinA-binding antibodies. Of evaluable patients exposed to RTP004 with either DAXI or placebo, 1.3% developed treatment-related anti–RTP004-binding antibodies, which were mostly transient. No patient developed binding antibodies to both daxibotulinumtoxinA and RTP004. All patients with treatment-related binding antibodies to daxibotulinumtoxinA or RTP004 achieved a clinical response (none or mild glabellar line severity) at Week 4 following each DAXI treatment cycle. The duration of clinical response was not different between treatment cycles when antibodies were detected vs when they were absent. Although the analysis population was small compared to the number of patients likely to receive repeated treatment in clinical practice, these results suggest that DAXI administration at the approved glabellar lines dose has low immunogenic potential and that nonneutralizing antibodies to daxibotulinumtoxinA or RTP004 occur infrequently and often transiently, and have no impact on clinical efficacy, safety, or duration of action. Real-world data encompassing larger numbers of patients is needed to substantiate these results. LEVEL OF EVIDENCE: 3: [Image: see text] Oxford University Press 2023-04-13 /pmc/articles/PMC10501746/ /pubmed/37051886 http://dx.doi.org/10.1093/asj/sjad101 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of The Aesthetic Society. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Special Topic
Humphrey, Shannon
Dover, Jeffrey S
Bowsher, Ronald R
Clancy, Amanda
Liu, Yan
Prawdzik, Gregg
Gallagher, Conor J
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
title Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
title_full Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
title_fullStr Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
title_full_unstemmed Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
title_short Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
title_sort immunogenicity of daxibotulinumtoxina for injection in glabellar lines
topic Special Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501746/
https://www.ncbi.nlm.nih.gov/pubmed/37051886
http://dx.doi.org/10.1093/asj/sjad101
work_keys_str_mv AT humphreyshannon immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines
AT doverjeffreys immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines
AT bowsherronaldr immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines
AT clancyamanda immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines
AT liuyan immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines
AT prawdzikgregg immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines
AT gallagherconorj immunogenicityofdaxibotulinumtoxinaforinjectioninglabellarlines